Alternative names

Technical specifications

• Antigen: CD336 (NKp44)
• Clone: REA1163
• Isotype: recombinant human IgG1
• Isotype control: REA Control (S) antibodies
• Alternative names of antigen: NCR2, LY95, NKp44
• Entrez Gene ID: 9436
• Molecular mass of antigen [kDa]: 28
• Distribution of antigen: NK cells, T cells
• Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
• Fixation: Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
• Storage: Store protected from light at 2–8 °C. Do not freeze.
• Available conjugates: PE, APC, PE-Vio770, VioBright 515, Biotin

• Figure 1

  CD56 + and CD14 + cells were isolated with CD56 MicroBeads and CD14 MicroBeads from human peripheral blood cells (PBMCs). CD56 + NK cells were stimulated with CD14 + monocytes and 1 ng/mL human IL-2 for 3 days. Cells were stained with CD336 (NKp44) antibodies or with the corresponding REA Control (S) antibodies (left images) as well as with CD56 antibodies. Flow cytometry was performed using the MACSQuant ® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

• Selected references

  1. Vitale, M. et al. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065-2072
  2. Sivori, S. et al. (2000) 2B4 functions as a co-receptor in human NK cell activation. Eur. J. Immunol. 30: 787-793
  3. Moretta, A. et al. (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223
  4. Chaput, N. et al. (2013)
     Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR

     ⁺

     NK cell levels correlate with disease outcome.
     Oncoimmunology 2(2): e23080